The THINC-it tool is currently being developed in Toronto, Canada, with support from the Mood Disorders Psychopharmacology Unit at the University of Toronto and the Brain and Cognition Discovery Foundation, and is anticipated to provide a free-of-charge service adaptable to various clinical settings, providing actionable information (eg, potential for patient stratification based on task performance) for clinicians and patients with subsequent validations planned in other languages (ie, Spanish, French, Chinese, Korean).1 The THINC-it tool is meant to assist individuals with MDD to identify aspects of their cognition that may be contributing to limitations in their work capacity; inform clinician treatment recommendations; and identify the extent to which impaired cognition affects work functioning by providing an objective stratification method for distinguishing inter- and intraindividual differences among people affected by depression.

In short, the recently estimated $210.5 billion cost of MDD to the workplace, with 48% to 50% of that cost attributable to workplace productivity losses and absenteeism, further underscores the hazards posed by cognitive impairment in MDD and demonstrates the need for better identifying and treating cognitive impairment in depression.2 Available evidence indicates that standard clinical interventions supplemented with accommodative strategies for returning to work, as well as modification of work responsibilities and expectations, may benefit employees affected by MDD until a systematic measurement of their cognitive function is developed — one that provides further information on how much cognitive function negatively affects work function and identifies targeted treatment for cognitive impairment in these individuals.   

Continue Reading


1. McIntyre RS, Lee Y. Cognition in major depressive disorder: a “Systemically Important Functional Index” (SIFI). Curr Opin Psychiatry. 2016;29(1):48-55.

2. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162.

3. de Graaf, Tuithof M, van DS, ten HM. Comparing the effects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol .2012;47(11):1873-1883.

4. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515-527.

5. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800.

6. Summergrad P. Addressing depression in the workplace. Psychiatr Serv. 2015;66(6):561.

7. de VG, Koeter MW, Nieuwenhuijsen K, Hees HL, Schene AH. Predictors of impaired work functioning in employees with major depression in remission. J Affect Disord. 2015;185:180-187.

8. Hees HL, Koeter MW, Schene AH. Longitudinal relationship between depressive symptoms and work outcomes in clinically treated patients with long-term sickness absence related to major depressive disorder. J Affect Disord. 2013;148(2-3):272-277.

9. McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279-282.

10. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029-2040.

11. Madhoo M, Keefe RS, Roth RM, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology. 2014;39(6):1388-1398.

12. Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine: a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf. 2015;14(8):1291-1304.

13. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557-1567.

14. Noordik E, Nieuwenhuijsen K, Varekamp I, van der Klink JJ, van Dijk FJ. Exploring the return-to-work process for workers partially returned to work and partially on long-term sick leave due to common mental disorders: a qualitative study. Disabil Rehabil. 2011;33(17-18):1625-1635.

15. Bender A, Farvolden P. Depression and the workplace: a progress report. Curr Psychiatry Rep. 2008;10(1):73-79.